LeonaBio Inc Dossier
Qualitative Analysis
Business overview
LeonaBio Inc. (formerly known as Athira Pharma, Inc., rebranded in January 2026) is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs. The company's expanded pipeline focuses on treatment-resistant metastatic breast cancer and neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS). LeonaBio's lead clinical assets are lasofoxifene, a late-stage selective estrogen receptor modulator (SERM) in Phase 3 development for metastatic breast cancer, and brelgometon (ATH-1105), an orally available, brain-penetrant small molecule targeting the hepatocyte growth factor (HGF) system for ALS.
Research as of 24 Jul 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the Phase 3 ELAINE-3 clinical trial evaluating lasofoxifene in combination with abemaciclib (a CDK4/6 inhibitor) for patients with ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer [3.3.2].
Expected impact: Aims to establish lasofoxifene as the endocrine therapy of choice and standard of care in a multi-billion dollar second-line metastatic breast cancer setting.
Transitioning brelgometon (ATH-1105), an oral, brain-penetrant small molecule positive modulator of the neurotrophic HGF system, from Phase 1 healthy volunteer testing into a Phase 2 proof-of-concept study in ALS patients.
Expected impact: To demonstrate clinical efficacy, safety, and biomarker modulation (such as neurofilament light chain) in patients suffering from ALS.
Rebranding the company from Athira Pharma, Inc. to LeonaBio, Inc. (ticker: LONA) to reflect a strategic shift toward a diversified, opportunity-driven pipeline following the in-licensing of lasofoxifene.
Expected impact: Aligns corporate identity with late-stage oncology and neurodegeneration assets, moving past previous clinical failures in Alzheimer's disease.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of exclusive global rights (excluding East Asia) to lasofoxifene, a Phase 3-ready selective estrogen receptor modulator (SERM) for metastatic breast cancer, pivoting the company into late-stage oncology.
Financial impact: LeonaBio issued a pre-funded warrant to purchase approximately 5.5 million shares of common stock (valued at ~$34.9 million) and agreed to pay $75,000 monthly (credited against future milestones). The company is also obligated to pay up to $100 million in commercialization/sales milestones plus low-single-digit royalties.
Strategic Partnerships
Secures the core late-stage asset (lasofoxifene) that forms the foundation of LeonaBio's oncology pipeline and corporate turnaround strategy.
Terms: Upfront consideration of a pre-funded warrant for 5.5 million shares, $75,000 monthly development credits, up to $100 million in regulatory and sales milestones, and low-single-digit royalties on net sales